In this article, new recommendations were made that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time). Plaquenil mixed with alcohol Hydroxychloroquine with vit d Fundus autofluorescence hydroxychloroquine Does hair loss differ when it is due to plaquenil This article is from June 2011 and may contain outdated material. Download PDF. Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. Hydroxychloroquine Toxicity Screening Is Key Hydroxychloroquine Plaquenil is a disease-modifying antirheumatic drug that is commonly used to reduce arthritic pain and swelling. The American Academy of Ophthalmology has published several dosing and screening recommendations for hydroxychloroquine to avoid potential retinal toxicity, yet some patients still experience. The previous AAO guideline recommended screening every 12 months. It has become fairly common practice for most rheumatologists to recommend that patients being treated with hydroxychloroquine be seen for formal visual field evaluation once or twice a year to monitor for retinal toxicity. Plaquenil toxicity aao Drug Toxicity to the Retina and Optic Nerve Are You Missing It., Drug Toxicity to the Retina and Optic Nerve Are You Missing. Aralene callahan Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine-Induced Retinal Toxicity - American.. Despite Plaquenil dosing recommendations, retinal toxicity remains. My Take on New Ocular Screening Guidelines for Plaquenil.. Aug 06, 2014 Hydroxychloroquine, sold under the brand name Plaquenil Sanofi-Aventis, is an antimalarial drug that has gained widespread use in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. 1 By some estimates, more than 150,000 patients are on long-term therapy with this medication in America alone. 2 Retinal toxicity associated with HCQ use is. Retinal toxicity Retinal toxicity, potentially causing irreversible retinopathy, is predominantly associated with high daily doses and a duration of 5 years of use of chloroquine or hydroxychloroquine in the treatment of rheumatic diseases. Other major risk factors include concurrent tamoxifen use. Dec 04, 2014 The incidence of HCQ retinopathy is very low. In fact, HCQ is estimated at having a 0.5% incidence of retinal toxicity after 5 years of therapy.5,6 Retinal toxicity secondary to HCQ is irreversible and can continue to progress following cessation of therapy. Prompt screening and serial monitoring, with the utilization of imaging modalities, is paramount importance to early detection.